Free Trial
→ Don't lose access to this (From TradeWins) (Ad)tc pixel
NASDAQ:IMNN

Imunon Q3 2026 Earnings Date & Estimates

Imunon logo
$0.91 +0.01 (+0.78%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$0.90 -0.01 (-1.10%)
As of 07:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Imunon is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for 11:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
11:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Imunon in Q3 2026

Imunon is expected to post earnings of -$0.61 per share. In the same quarter a year earlier Imunon reported -$1.16 per share. Imunon last reported on August 11, 2026, posting -$0.54 per share and beating the -$0.8675 consensus estimate. Imunon has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.61
Prior-Year EPS
-$1.16

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.54 (Beat by +$0.3275)
EPS Beat Rate
8 of last 8 quarters

Prepare for the Q3 2026 Call

Imunon Q3 2026 Earnings FAQ

Imunon (NASDAQ:IMNN) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Imunon's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 11:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Imunon to post earnings of -$0.61 per share for Q3 2026.

Imunon Earnings Headlines

IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026
November 2 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/02/3393165/0/en/imunon-to-hold-third-quarter-2026-financial-results-and-business-update-conference-call-on-thursday-november-12-2026.html
Imunon Updates Investor Presentation for Upcoming Engagements
October 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/imunon-updates-investor-presentation-for-upcoming-engagements?utm_source=marketbeat.com&utm_medium=referral
Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.tc pixel
November 5 at 1:00 AM  |  TradeWins (Ad)
IMUNON To Sell ThermoDox Rights To VoxelDox For Glioblastoma Multiforme
October 21, 2026  |  rttnews.comhttps://www.rttnews.com/3701173/imunon-to-sell-thermodox-rights-to-voxeldox-for-glioblastoma-multiforme.aspx
IMUNON Announces Strategic Sale of ThermoDox®
October 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385502/0/en/imunon-announces-strategic-sale-of-thermodox.html
IMUNON to Participate in Upcoming Investor Conferences
October 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/08/3377351/0/en/imunon-to-participate-in-upcoming-investor-conferences.html
See More Imunon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Imunon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Imunon and other key companies, straight to your email.

About Imunon

Imunon (NASDAQ:IMNN) (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing treatments for cancer and other serious diseases. The company uses proprietary nucleic acid delivery technologies to develop therapeutic candidates designed to stimulate the immune system or deliver genetic instructions directly to target cells.

Imunon’s lead program is GEN-1, an investigational interleukin-12 gene-mediated immunotherapy intended to treat ovarian cancer. The company has evaluated GEN-1 in combination with chemotherapy and other treatments in clinical studies. Imunon’s technology platforms are also intended to support the development of DNA- and RNA-based medicines, including potential vaccines and immunotherapies.

The company was formerly known as Celsion Corporation and adopted the Imunon name as it concentrated its business on immunotherapy and nucleic acid-based therapeutic approaches. Imunon is headquartered in Lawrenceville, New Jersey, and its activities are primarily focused on research, clinical development, and potential commercialization of its proprietary biotechnology programs.

View Imunon Profile
Earnings Tools